cinacalcet ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
calcium-sensing receptors (CaSR) agonists 647 226256-56-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cinacalcet
  • mimpara
  • cinacalcet hydrochloride
  • sensipar
  • AMG 073
  • AMG-073
  • KRN1493
  • cinacalcet HCl
  • Molecular weight: 357.42
  • Formula: C22H22F3N
  • CLOGP: 6.35
  • LIPINSKI: 1
  • HAC: 1
  • HDO: 1
  • TPSA: 12.03
  • ALOGS: -6.81
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
60 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 7.19 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 20 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 17.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 18.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 19.90 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 22, 2004 EMA
March 8, 2004 FDA AMGEN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hospitalisation 8523.27 22.01 2557 24047 65380 50513140
Product dose omission issue 6899.87 22.01 2810 23794 181028 50397492
Laboratory test abnormal 6124.59 22.01 1572 25032 21636 50556884
Adverse drug reaction 1286.00 22.01 611 25993 54611 50523909
Intentional product misuse 895.27 22.01 453 26151 46281 50532239
Blood parathyroid hormone increased 844.88 22.01 213 26391 2641 50575879
Blood parathyroid hormone abnormal 478.18 22.01 85 26519 130 50578390
Hospice care 339.38 22.01 124 26480 5648 50572872
Arteriovenous fistula site complication 322.26 22.01 70 26534 423 50578097
Adverse event 253.94 22.01 199 26405 43564 50534956
Living in residential institution 248.37 22.01 56 26548 411 50578109
Calciphylaxis 225.77 22.01 75 26529 2563 50575957
Hypocalcaemia 223.89 22.01 152 26452 26664 50551856
Death 219.27 22.01 509 26095 324870 50253650
Blood calcium increased 208.77 22.01 95 26509 7624 50570896
Rehabilitation therapy 208.66 22.01 60 26544 1253 50577267
Decreased appetite 199.51 22.01 369 26235 200554 50377966
Hypophagia 184.81 22.01 137 26467 27591 50550929
Nausea 180.11 22.01 788 25816 704610 49873910
Malaise 179.67 22.01 481 26123 335051 50243469
Transplant 165.28 22.01 43 26561 607 50577913
Blood calcium decreased 148.60 22.01 107 26497 20599 50557921
Blood calcium abnormal 147.77 22.01 44 26560 1042 50577478
Renal transplant 147.00 22.01 45 26559 1174 50577346
Vomiting 136.02 22.01 539 26065 460219 50118301
Blood parathyroid hormone decreased 130.15 22.01 67 26537 7047 50571473
Parathyroid tumour benign 124.14 22.01 34 26570 590 50577930
Parathyroidectomy 122.60 22.01 28 26576 219 50578301
Unevaluable investigation 122.55 22.01 21 26583 22 50578498
Nephrogenic systemic fibrosis 119.41 22.01 54 26550 4268 50574252
Fatigue 108.57 22.01 128 26476 707473 49871047
Peritonitis bacterial 100.28 22.01 49 26555 4612 50573908
Arthralgia 90.40 22.01 60 26544 438642 50139878
Abdominal discomfort 90.14 22.01 297 26307 231344 50347176
Hungry bone syndrome 89.00 22.01 18 26586 72 50578448
Blood phosphorus increased 86.68 22.01 37 26567 2545 50575975
Rheumatoid arthritis 86.39 22.01 5 26599 202545 50375975
Hypercalcaemia 84.19 22.01 81 26523 23271 50555249
Brown tumour 80.54 22.01 15 26589 34 50578486
Gastrointestinal tube insertion 79.65 22.01 27 26577 982 50577538
Mastication disorder 73.70 22.01 30 26574 1830 50576690
Pyrexia 73.02 22.01 56 26548 380147 50198373
Pain 71.45 22.01 122 26482 578781 49999739
Dialysis 70.51 22.01 50 26554 9388 50569132
Joint swelling 70.06 22.01 21 26583 245265 50333255
Skin induration 66.84 22.01 32 26572 2879 50575641
Hyperparathyroidism 63.03 22.01 29 26575 2385 50576135
Blood phosphorus abnormal 62.66 22.01 15 26589 147 50578373
Sinusitis 60.10 22.01 9 26595 170549 50407971
Hepatic enzyme increased 59.77 22.01 3 26601 137377 50441143
Condition aggravated 57.95 22.01 43 26561 297015 50281505
Product use issue 57.25 22.01 6 26598 149469 50429051
Drug ineffective 55.31 22.01 233 26371 819100 49759420
Arteriovenous fistula occlusion 54.38 22.01 16 26588 363 50578157
Arthropathy 54.12 22.01 9 26595 157897 50420623
Toxicity to various agents 50.95 22.01 24 26580 212475 50366045
Systemic lupus erythematosus 50.51 22.01 7 26597 140615 50437905
Parathyroid tumour malignant 50.14 22.01 9 26595 15 50578505
Gastrostomy 49.21 22.01 16 26588 510 50578010
Abdominal pain upper 48.79 22.01 189 26415 159120 50419400
Skin hypertrophy 47.69 22.01 26 26578 3069 50575451
Neutropenia 47.36 22.01 10 26594 147955 50430565
Unevaluable event 46.01 22.01 85 26519 45981 50532539
Skin fibrosis 45.14 22.01 17 26587 842 50577678
Hypervolaemia 44.88 22.01 61 26543 25438 50553082
Blue toe syndrome 44.79 22.01 14 26590 392 50578128
Treatment failure 44.67 22.01 9 26595 137628 50440892
Enteral nutrition 44.50 22.01 9 26595 36 50578484
Therapeutic product effect decreased 43.94 22.01 9 26595 136041 50442479
Peritonitis 43.57 22.01 47 26557 15439 50563081
Skin tightness 42.96 22.01 26 26578 3737 50574783
Stomatitis 41.70 22.01 3 26601 101341 50477179
Injection site pain 41.13 22.01 5 26599 111019 50467501
Glossodynia 40.92 22.01 6 26598 115563 50462957
Hyperphosphataemia 38.25 22.01 19 26585 1852 50576668
Swelling 37.96 22.01 30 26574 200842 50377678
Rash 37.66 22.01 112 26492 437359 50141161
Surgery 37.02 22.01 61 26543 30144 50548376
Drug hypersensitivity 36.58 22.01 47 26557 250963 50327557
Weight increased 35.87 22.01 32 26572 201859 50376661
End stage renal disease 35.21 22.01 27 26577 5710 50572810
Pelvic deformity 34.32 22.01 10 26594 219 50578301
Thyroid operation 33.31 22.01 9 26595 148 50578372
White blood cell count decreased 33.27 22.01 10 26594 116712 50461808
Parathyroid disorder 32.71 22.01 12 26592 552 50577968
Neuropathy peripheral 32.08 22.01 6 26598 96751 50481769
Arteriovenous fistula site infection 31.58 22.01 7 26597 47 50578473
Alanine aminotransferase increased 30.34 22.01 5 26599 88354 50490166
Peritoneal dialysis complication 30.24 22.01 14 26590 1167 50577353
Wrong technique in product usage process 29.91 22.01 80 26524 55430 50523090
Contusion 29.55 22.01 11 26593 112172 50466348
Cerebrovascular accident 29.50 22.01 113 26491 94567 50483953
Parathyroid hyperplasia 29.25 22.01 8 26596 138 50578382
Dyspnoea 28.60 22.01 170 26434 547438 50031082
Joint contracture 28.34 22.01 15 26589 1669 50576851
Product use in unapproved indication 27.86 22.01 13 26591 115806 50462714
Treatment noncompliance 26.85 22.01 53 26551 30097 50548423
Shunt occlusion 26.35 22.01 10 26594 506 50578014
Cardiac operation 26.10 22.01 17 26587 2778 50575742
Hyperparathyroidism tertiary 26.09 22.01 5 26599 14 50578506
Malignant neoplasm progression 25.40 22.01 3 26601 68121 50510399
Dysphagia 25.37 22.01 94 26510 77424 50501096
Adjusted calcium decreased 25.26 22.01 7 26597 127 50578393
Wound 25.25 22.01 12 26592 105782 50472738
Headache 25 22.01 160 26444 506375 50072145
Platelet count decreased 24.70 22.01 11 26593 100715 50477805
Alopecia 23.84 22.01 59 26545 244988 50333532
Aspartate aminotransferase increased 23.50 22.01 6 26598 77992 50500528
Nephrocalcinosis 23.25 22.01 11 26593 963 50577557
Chronic kidney disease-mineral and bone disorder 23.24 22.01 6 26598 82 50578438
Arteriovenous fistula site haemorrhage 23.00 22.01 7 26597 179 50578341
High turnover osteopathy 22.50 22.01 5 26599 34 50578486
Arteriovenous fistula thrombosis 22.49 22.01 7 26597 193 50578327
Wheezing 22.48 22.01 3 26601 62044 50516476

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product dose omission issue 7475.63 21.36 2730 19041 93653 29459103
Hospitalisation 6809.23 21.36 2125 19646 43863 29508893
Laboratory test abnormal 5831.15 21.36 1539 20232 16646 29536110
Adverse drug reaction 1051.37 21.36 457 21314 23563 29529193
Intentional product misuse 726.86 21.36 399 21372 34262 29518494
Blood parathyroid hormone increased 628.67 21.36 155 21616 1200 29551556
Blood parathyroid hormone abnormal 474.19 21.36 85 21686 76 29552680
Arteriovenous fistula site complication 375.68 21.36 82 21689 340 29552416
Adverse event 219.50 21.36 138 21633 15153 29537603
Transplant 212.08 21.36 57 21714 640 29552116
Blood calcium increased 197.03 21.36 78 21693 3141 29549615
Hospice care 190.88 21.36 87 21684 4981 29547775
Hypocalcaemia 190.77 21.36 142 21629 20523 29532233
Parathyroidectomy 183.39 21.36 35 21736 58 29552698
Blood parathyroid hormone decreased 171.26 21.36 50 21721 774 29551982
Living in residential institution 163.30 21.36 39 21732 259 29552497
Abdominal discomfort 162.44 21.36 188 21583 47715 29505041
Blood calcium abnormal 146.15 21.36 39 21732 425 29552331
Nausea 140.80 21.36 499 21272 288756 29264000
Blood calcium decreased 129.55 21.36 82 21689 9100 29543656
Rehabilitation therapy 129.33 21.36 38 21733 602 29552154
Hypophagia 128.06 21.36 113 21658 20759 29531997
Calciphylaxis 120.11 21.36 40 21731 972 29551784
Blood phosphorus increased 117.32 21.36 52 21719 2785 29549971
Renal transplant 112.44 21.36 43 21728 1575 29551181
Vomiting 109.77 21.36 374 21397 211886 29340870
Unevaluable investigation 100.98 21.36 18 21753 15 29552741
Acute kidney injury 90.83 21.36 41 21730 265226 29287530
Parathyroid tumour benign 88.71 21.36 20 21751 99 29552657
Toxicity to various agents 83.17 21.36 14 21757 173647 29379109
Death 82.67 21.36 480 21291 341604 29211152
Hypercalcaemia 78.07 21.36 69 21702 12690 29540066
Abdominal pain upper 76.09 21.36 150 21621 60843 29491913
Malaise 76.07 21.36 274 21497 159328 29393428
Hungry bone syndrome 74.56 21.36 16 21755 60 29552696
Pyrexia 69.29 21.36 66 21705 287556 29265200
Neutropenia 66.74 21.36 9 21762 131702 29421054
Peritonitis bacterial 63.25 21.36 44 21727 5712 29547044
Parathyroid disorder 57.48 21.36 12 21759 38 29552718
Gastrointestinal disorder 55.94 21.36 86 21685 28620 29524136
Surgery 55.33 21.36 55 21716 11724 29541032
Gastrostomy 51.27 21.36 19 21752 637 29552119
Decreased appetite 50.32 21.36 226 21545 145116 29407640
Drug interaction 48.98 21.36 44 21727 197341 29355415
Parathyroid tumour malignant 48.76 21.36 9 21762 11 29552745
Nephrogenic systemic fibrosis 47.73 21.36 32 21739 3910 29548846
Gastrointestinal tube insertion 47.66 21.36 21 21750 1108 29551648
Parathyroid hyperplasia 47.18 21.36 8 21763 3 29552753
Mastication disorder 47.11 21.36 21 21750 1139 29551617
Fatigue 41.67 21.36 109 21662 316712 29236044
Blood phosphorus abnormal 41.54 21.36 11 21760 116 29552640
Adjusted calcium decreased 41.01 21.36 7 21764 3 29552753
Unevaluable event 40.35 21.36 76 21695 29775 29522981
Treatment noncompliance 39.57 21.36 67 21704 24160 29528596
Dialysis 39.55 21.36 43 21728 10165 29542591
Condition aggravated 39.49 21.36 30 21741 146265 29406491
Hyperparathyroidism 38.07 21.36 18 21753 1119 29551637
Gastric disorder 37.88 21.36 43 21728 10661 29542095
Platelet count decreased 37.60 21.36 15 21756 104657 29448099
Dyspnoea 36.72 21.36 121 21650 326611 29226145
Leg amputation 35.68 21.36 21 21750 2043 29550713
Overdose 34.87 21.36 8 21763 79811 29472945
Hyperphosphataemia 34.11 21.36 21 21750 2217 29550539
Alanine aminotransferase increased 33.29 21.36 6 21765 70938 29481818
Disease progression 32.39 21.36 10 21761 81906 29470850
Confusional state 32.29 21.36 28 21743 127849 29424907
Shunt stenosis 31.65 21.36 13 21758 576 29552180
White blood cell count decreased 31.52 21.36 11 21760 83351 29469405
Brown tumour 31.08 21.36 5 21766 0 29552756
Product use in unapproved indication 30.30 21.36 13 21758 86862 29465894
Haemoglobin increased 29.24 21.36 21 21750 2865 29549891
Shunt occlusion 28.86 21.36 13 21758 723 29552033
Peritonitis 28.29 21.36 44 21727 14780 29537976
Skin induration 28.10 21.36 18 21753 2036 29550720
Anaemia 28.01 21.36 67 21704 200884 29351872
Appetite disorder 27.96 21.36 18 21753 2054 29550702
Neuropathy peripheral 27.49 21.36 9 21762 71018 29481738
Pulmonary embolism 27.42 21.36 11 21760 76523 29476233
Hyponatraemia 27.20 21.36 8 21763 67625 29485131
Thyroid operation 27.14 21.36 5 21766 6 29552750
Thrombocytopenia 26.83 21.36 36 21735 134787 29417969
Vestibular neuronitis 25.21 21.36 8 21763 166 29552590
Rhabdomyolysis 24.81 21.36 7 21764 60801 29491955
Hyperparathyroidism secondary 24.78 21.36 14 21757 1261 29551495
Wrong technique in product usage process 24.30 21.36 64 21707 31364 29521392
Aspartate aminotransferase increased 24.14 21.36 7 21764 59718 29493038
Pancytopenia 23.80 21.36 16 21755 83152 29469604
Weight decreased 23.75 21.36 47 21724 150858 29401898
Parathyroid gland enlargement 23.14 21.36 7 21764 123 29552633
Drug effective for unapproved indication 23.06 21.36 14 21757 1441 29551315
Product use issue 22.77 21.36 5 21766 51439 29501317
Nephrocalcinosis 22.46 21.36 10 21761 541 29552215
Tachycardia 22.00 21.36 13 21758 72397 29480359
Dehydration 21.47 21.36 32 21739 114716 29438040

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Laboratory test abnormal 9690.85 16.86 2292 31984 21771 64442685
Hospitalisation 5978.55 16.86 2014 32262 73193 64391263
Product dose omission issue 3137.00 16.86 1678 32598 193069 64271387
Blood parathyroid hormone increased 1010.43 16.86 251 34025 2883 64461573
Blood parathyroid hormone abnormal 742.17 16.86 134 34142 232 64464224
Arteriovenous fistula site complication 716.14 16.86 151 34125 765 64463691
Adverse drug reaction 545.20 16.86 325 33951 45139 64419317
Nausea 459.31 16.86 1168 33108 784632 63679824
Vomiting 367.30 16.86 863 33413 550254 63914202
Decreased appetite 351.78 16.86 575 33701 280714 64183742
Living in residential institution 345.76 16.86 77 34199 524 64463932
Calciphylaxis 309.93 16.86 101 34175 3211 64461245
Rehabilitation therapy 298.95 16.86 82 34194 1416 64463040
Death 280.68 16.86 718 33558 481987 63982469
Abdominal discomfort 269.69 16.86 403 33873 181919 64282537
Hypocalcaemia 269.03 16.86 203 34073 41550 64422906
Blood calcium increased 251.75 16.86 112 34164 8430 64456026
Unevaluable investigation 234.01 16.86 39 34237 28 64464428
Malaise 218.19 16.86 578 33698 395669 64068787
Blood calcium abnormal 197.30 16.86 57 34219 1197 64463259
Parathyroid tumour benign 186.24 16.86 48 34228 644 64463812
Renal transplant 180.16 16.86 61 34215 2187 64462269
Intentional product misuse 177.09 16.86 205 34071 72090 64392366
Muscle spasms 175.32 16.86 288 33988 140735 64323721
Blood phosphorus increased 162.44 16.86 70 34206 4876 64459580
Blood calcium decreased 159.59 16.86 122 34154 25432 64439024
Abdominal pain upper 159.31 16.86 312 33964 174718 64289738
Hungry bone syndrome 150.45 16.86 31 34245 137 64464319
Peritonitis bacterial 149.87 16.86 80 34196 8963 64455493
Blood parathyroid hormone decreased 141.65 16.86 72 34204 7294 64457162
Parathyroidectomy 133.78 16.86 29 34247 171 64464285
Hypercalcaemia 131.57 16.86 119 34157 31297 64433159
Nephrogenic systemic fibrosis 126.30 16.86 62 34214 5830 64458626
Unevaluable event 119.97 16.86 141 34135 50348 64414108
Hyperparathyroidism 102.39 16.86 43 34233 2809 64461647
Toxicity to various agents 97.06 16.86 36 34240 363477 64100979
Brown tumour 92.21 16.86 17 34259 35 64464421
Surgery 91.81 16.86 93 34183 28120 64436336
Adjusted calcium decreased 88.81 16.86 20 34256 144 64464312
Pyrexia 88.63 16.86 100 34176 558544 63905912
Dialysis 84.76 16.86 71 34205 16849 64447607
Transplant 83.05 16.86 27 34249 851 64463605
Febrile neutropenia 82.99 16.86 4 34272 187653 64276803
Parathyroid tumour malignant 81.98 16.86 15 34261 29 64464427
Skin induration 80.82 16.86 41 34235 4134 64460322
Gastrointestinal tube insertion 76.53 16.86 29 34247 1445 64463011
Neutropenia 76.29 16.86 17 34259 239607 64224849
Gastric disorder 75.15 16.86 85 34191 29112 64435344
Shunt occlusion 74.20 16.86 27 34249 1200 64463256
Rheumatoid arthritis 71.08 16.86 4 34272 164290 64300166
Hypophagia 70.85 16.86 96 34180 39491 64424965
Parathyroid disorder 69.81 16.86 20 34256 407 64464049
Gastrostomy 68.13 16.86 24 34252 970 64463486
Condition aggravated 66.58 16.86 60 34216 372366 64092090
Hyperphosphataemia 65.34 16.86 35 34241 3946 64460510
Drug interaction 63.93 16.86 59 34217 362024 64102432
Arthralgia 60.90 16.86 88 34188 442172 64022284
Arteriovenous fistula occlusion 60.65 16.86 19 34257 530 64463926
Fatigue 59.52 16.86 202 34074 748528 63715928
Shunt stenosis 59.06 16.86 22 34254 1045 64463411
Blood phosphorus abnormal 58.72 16.86 16 34260 269 64464187
Acute kidney injury 57.43 16.86 94 34182 449146 64015310
Peritonitis 56.31 16.86 68 34208 24955 64439501
Skin hypertrophy 55.82 16.86 33 34243 4496 64459960
Skin tightness 55.59 16.86 34 34242 4927 64459529
Joint swelling 54.67 16.86 23 34253 215359 64249097
Hypervolaemia 52.70 16.86 82 34194 38203 64426253
Hepatic enzyme increased 50.99 16.86 5 34271 129938 64334518
Leg amputation 50.35 16.86 28 34248 3399 64461057
Diarrhoea 50.19 16.86 595 33681 722109 63742347
Product use issue 49.83 16.86 10 34266 151705 64312751
Peritoneal dialysis complication 49.41 16.86 24 34252 2204 64462252
Sinusitis 49.24 16.86 9 34267 145919 64318537
End stage renal disease 48.46 16.86 42 34234 10433 64454023
Skin fibrosis 45.78 16.86 20 34256 1439 64463017
Injection site pain 44.47 16.86 4 34272 111404 64353052
Alanine aminotransferase increased 43.95 16.86 10 34266 139021 64325435
Pelvic deformity 43.93 16.86 10 34266 76 64464380
Parathyroid gland enlargement 43.58 16.86 11 34265 135 64464321
White blood cell count decreased 43.13 16.86 15 34261 157822 64306634
Appetite disorder 42.87 16.86 32 34244 6429 64458027
Parathyroid hyperplasia 41.92 16.86 11 34265 159 64464297
Platelet count decreased 40.83 16.86 19 34257 167692 64296764
Cardiac operation 40.00 16.86 26 34250 4188 64460268
Blue toe syndrome 39.78 16.86 14 34262 564 64463892
High turnover osteopathy 39.47 16.86 8 34268 32 64464424
Arteriovenous fistula thrombosis 37.12 16.86 13 34263 516 64463940
Parathyroid haemorrhage 36.81 16.86 6 34270 3 64464453
Arteriovenous fistula site infection 36.48 16.86 10 34266 172 64464284
Therapeutic procedure 36.46 16.86 14 34262 723 64463733
Stomatitis 36.45 16.86 7 34269 109598 64354858
Angina pectoris 34.59 16.86 75 34201 45006 64419450
Product use in unapproved indication 34.55 16.86 26 34250 176592 64287864
Shunt infection 34.30 16.86 9 34267 130 64464326
Drug ineffective 33.49 16.86 286 33990 839961 63624495
Neuropathy peripheral 32.39 16.86 11 34265 117514 64346942
Arthropathy 32.18 16.86 12 34264 120955 64343501
Weight increased 31.78 16.86 40 34236 213308 64251148
Wrong technique in product usage process 31.76 16.86 91 34185 64883 64399573
Aspartate aminotransferase increased 31.67 16.86 12 34264 119776 64344680
Joint contracture 31.50 16.86 18 34258 2301 64462155
Nephrocalcinosis 31.49 16.86 15 34261 1319 64463137
Hyperparathyroidism secondary 31.42 16.86 18 34258 2312 64462144
Constipation 31.36 16.86 219 34057 229118 64235338
Treatment noncompliance 30.72 16.86 70 34206 43412 64421044
Fistula repair 30.55 16.86 7 34269 55 64464401
Confusional state 29.41 16.86 59 34217 261085 64203371
Blood pressure increased 29.37 16.86 29 34247 172523 64291933
Rash 29.13 16.86 135 34141 458414 64006042
Paraesthesia 29.11 16.86 145 34131 134377 64330079
Dyspnoea 28.88 16.86 244 34032 718430 63746026
Gastrointestinal disorder 28.87 16.86 109 34167 89600 64374856
Haemoglobin increased 28.50 16.86 23 34253 5178 64459278
Thyroid operation 28.20 16.86 8 34268 157 64464299
Arrhythmia 27.69 16.86 76 34200 52868 64411588
Toe amputation 27.02 16.86 19 34257 3481 64460975
Arteriovenous fistula site haemorrhage 26.70 16.86 9 34267 318 64464138
Therapeutic product effect decreased 26.66 16.86 14 34262 115337 64349119
Hospice care 26.39 16.86 26 34250 7599 64456857
Phosphaturic mesenchymal tumour 26.16 16.86 4 34272 0 64464456
Lower respiratory tract infection 25.82 16.86 9 34267 94605 64369851
Cerebrovascular accident 25.44 16.86 142 34134 137441 64327015
Psoriasis 25.11 16.86 4 34272 71699 64392757
Parathyroid gland operation 24.67 16.86 5 34271 20 64464436
Intentional product use issue 24.47 16.86 10 34266 95354 64369102
Treatment failure 24.42 16.86 16 34260 116800 64347656
Hypercalciuria 24.23 16.86 9 34267 424 64464032
Fibrosis 24.01 16.86 20 34256 4708 64459748
Medical procedure 23.97 16.86 8 34268 274 64464182
Hepatic cyst infection 23.79 16.86 7 34269 157 64464299
Overdose 23.67 16.86 30 34246 159536 64304920
Neoplasm malignant 23.60 16.86 45 34231 24643 64439813
Pain 23.53 16.86 185 34091 553326 63911130
Mucosal inflammation 23.06 16.86 3 34273 62581 64401875
Adverse event 23.00 16.86 59 34217 39430 64425026
Hyperparathyroidism tertiary 22.92 16.86 4 34272 5 64464451
Thrombosis in device 22.79 16.86 20 34256 5051 64459405
Chronic kidney disease-mineral and bone disorder 22.78 16.86 9 34267 502 64463954
Intracardiac mass 22.41 16.86 6 34270 94 64464362
Hypotension 22.18 16.86 304 33972 380670 64083786
Skin hyperpigmentation 22.05 16.86 22 34254 6529 64457927
Wheezing 21.42 16.86 8 34268 80571 64383885
Rhabdomyolysis 21.39 16.86 11 34265 91715 64372741
Blood pressure abnormal 21.39 16.86 32 34244 14403 64450053
Pericarditis 20.77 16.86 4 34272 62512 64401944
Pancytopenia 20.18 16.86 28 34248 143281 64321175
Syncope 20.07 16.86 33 34243 157602 64306854
Foot amputation 20.04 16.86 9 34267 692 64463764
Intermittent claudication 19.98 16.86 15 34261 3039 64461417
Deep vein thrombosis 19.91 16.86 16 34260 105166 64359290
Glossodynia 19.75 16.86 5 34271 64691 64399765
Parathyroid cyst 19.62 16.86 3 34273 0 64464456
Drug hypersensitivity 19.58 16.86 63 34213 237752 64226704
Liver function test abnormal 19.32 16.86 4 34272 59397 64405059
Swelling 19.07 16.86 35 34241 160183 64304273
Cardiac disorder 18.94 16.86 69 34207 55747 64408709
Blood phosphorus decreased 18.91 16.86 19 34257 5686 64458770
Systemic lupus erythematosus 18.56 16.86 9 34267 77603 64386853
Renal cyst infection 18.43 16.86 6 34270 190 64464266
Anaemia 18.27 16.86 122 34154 378558 64085898
Gangrene 18.26 16.86 21 34255 7317 64457139
Oxygen saturation decreased 18.24 16.86 18 34258 107158 64357298
Calcinosis 18.22 16.86 12 34264 1976 64462480
Joint range of motion decreased 18.17 16.86 35 34241 19308 64445148
Anaphylactic reaction 17.94 16.86 7 34269 68657 64395799
Product dispensing issue 17.93 16.86 5 34271 92 64464364
Extremity contracture 17.86 16.86 11 34265 1614 64462842
Oncocytoma 17.62 16.86 4 34272 30 64464426
Nasal congestion 17.48 16.86 5 34271 59653 64404803
Vestibular neuronitis 17.42 16.86 8 34268 648 64463808
Poor peripheral circulation 17.22 16.86 14 34262 3186 64461270
Blood glucose decreased 17.20 16.86 38 34238 23085 64441371
Hyponatraemia 17.13 16.86 33 34243 148306 64316150
Blood cholesterol increased 17.07 16.86 3 34273 50063 64414393
Depression 16.93 16.86 46 34230 183245 64281211

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC H05BX01 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
CALCIUM HOMEOSTASIS
ANTI-PARATHYROID AGENTS
Other anti-parathyroid agents
FDA MoA N0000020081 Increased Calcium-sensing Receptor Sensitivity
MeSH PA D057966 Calcimimetic Agents
MeSH PA D000077264 Calcium-Regulating Hormones and Agents
MeSH PA D006727 Hormone Antagonists
FDA EPC N0000175902 Calcium-sensing Receptor Agonist
CHEBI has role CHEBI:48525 calcimimetics
CHEBI has role CHEBI:50183 P450 inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypercalcemia due to Primary Hyperparathyroidism indication
Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis indication
Parathyroid Carcinoma with Hypercalcemia indication
Hypophosphatemia contraindication 4996001
Hypocalcemia contraindication 5291005
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Seizure disorder contraindication 128613002
Disease of liver contraindication 235856003 DOID:409
Adynamic bone disease contraindication 236552002




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.69 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 30MG BASE SENSIPAR AMGEN N021688 March 8, 2004 RX TABLET ORAL 7829595 Sept. 22, 2026 METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
EQ 60MG BASE SENSIPAR AMGEN N021688 March 8, 2004 RX TABLET ORAL 7829595 Sept. 22, 2026 METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
EQ 90MG BASE SENSIPAR AMGEN N021688 March 8, 2004 RX TABLET ORAL 7829595 Sept. 22, 2026 METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Extracellular calcium-sensing receptor GPCR POSITIVE ALLOSTERIC MODULATOR EC50 7.70 CHEMBL CHEMBL
Cytochrome P450 2D6 Enzyme IC50 7.30 CHEMBL
Glycine receptor subunit alpha-1 Ion channel EC50 6.49 CHEMBL
Metabotropic glutamate receptor 5 GPCR ALLOSTERIC MODULATOR Ki 4.35 IUPHAR

External reference:

IDSource
4021430 VUID
N0000148841 NUI
D03504 KEGG_DRUG
364782-34-3 SECONDARY_CAS_RN
384379 RXNORM
4021430 VANDF
C1337242 UMLSCUI
CHEBI:48390 CHEBI
YP4 PDB_CHEM_ID
CHEMBL1201284 ChEMBL_ID
CHEMBL1200776 ChEMBL_ID
DB01012 DRUGBANK_ID
D000069449 MESH_DESCRIPTOR_UI
156419 PUBCHEM_CID
3308 IUPHAR_LIGAND_ID
8287 INN_ID
UAZ6V7728S UNII
18133 MMSL
303128 MMSL
49840 MMSL
d05218 MMSL
008595 NDDF
008596 NDDF
409391006 SNOMEDCT_US
409392004 SNOMEDCT_US
426512007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 0904-7067 TABLET, FILM COATED 30 mg ORAL ANDA 25 sections
Cinacalcet Human Prescription Drug Label 1 16714-078 TABLET, FILM COATED 30 mg ORAL ANDA 27 sections
Cinacalcet Human Prescription Drug Label 1 16714-079 TABLET, FILM COATED 60 mg ORAL ANDA 27 sections
Cinacalcet Human Prescription Drug Label 1 16714-080 TABLET, FILM COATED 90 mg ORAL ANDA 27 sections
CINACALCET HUMAN PRESCRIPTION DRUG LABEL 1 16729-440 TABLET, FILM COATED 30 mg ORAL ANDA 25 sections
CINACALCET HUMAN PRESCRIPTION DRUG LABEL 1 16729-441 TABLET, FILM COATED 60 mg ORAL ANDA 25 sections
CINACALCET HUMAN PRESCRIPTION DRUG LABEL 1 16729-442 TABLET, FILM COATED 90 mg ORAL ANDA 25 sections
Cinacalcet Human Prescription Drug Label 1 31722-103 TABLET, FILM COATED 30 mg ORAL ANDA 29 sections
Cinacalcet Human Prescription Drug Label 1 31722-104 TABLET, FILM COATED 60 mg ORAL ANDA 29 sections
Cinacalcet Human Prescription Drug Label 1 31722-105 TABLET, FILM COATED 90 mg ORAL ANDA 29 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 42291-459 TABLET, FILM COATED 30 mg ORAL ANDA 25 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 42291-460 TABLET, FILM COATED 60 mg ORAL ANDA 25 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 42291-461 TABLET, FILM COATED 90 mg ORAL ANDA 25 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 42543-961 TABLET, FILM COATED 30 mg ORAL ANDA 23 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 42543-962 TABLET, FILM COATED 60 mg ORAL ANDA 23 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 42543-963 TABLET, FILM COATED 90 mg ORAL ANDA 23 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 43598-367 TABLET 30 mg ORAL ANDA 24 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 43598-368 TABLET 60 mg ORAL ANDA 24 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 43598-369 TABLET 90 mg ORAL ANDA 24 sections
Cinacalcet Human Prescription Drug Label 1 47335-379 TABLET, FILM COATED 30 mg ORAL ANDA 27 sections
Cinacalcet Human Prescription Drug Label 1 47335-380 TABLET, FILM COATED 60 mg ORAL ANDA 27 sections
Cinacalcet Human Prescription Drug Label 1 47335-600 TABLET, FILM COATED 90 mg ORAL ANDA 27 sections
Sensipar HUMAN PRESCRIPTION DRUG LABEL 1 50090-3529 TABLET, COATED 30 mg ORAL NDA 28 sections
Sensipar HUMAN PRESCRIPTION DRUG LABEL 1 50090-4470 TABLET, COATED 30 mg ORAL NDA 26 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 50268-153 TABLET 30 mg ORAL ANDA 24 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 51407-295 TABLET, FILM COATED 30 mg ORAL ANDA 23 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 51407-296 TABLET, FILM COATED 60 mg ORAL ANDA 23 sections
Cinacalcet HUMAN PRESCRIPTION DRUG LABEL 1 51407-297 TABLET, FILM COATED 90 mg ORAL ANDA 23 sections
Sensipar HUMAN PRESCRIPTION DRUG LABEL 1 53808-0577 TABLET, COATED 30 mg ORAL NDA 26 sections
Sensipar HUMAN PRESCRIPTION DRUG LABEL 1 53808-0578 TABLET, COATED 60 mg ORAL NDA 26 sections